Merck up on Niaspin-Zetia study
The drug giant's shares rose 2% after results of a clinical trial of its cholesterol drug Zetia were not as negative as some analysts had expected. A new study showed Abbott Laboratories' (ABT) drug Niaspin appeared more effective than Merck's (MRK) Zetia as a supplementary cholesterol treatment to statins. But the New England Journal of Medicine questioned the study, saying the study was prematurely terminated. Abbott Labs rose 1%.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here